Nexien Biopharma Company Executives
| NXEN Stock | USD 0.01 0.01 35.00% |
Nexien Biopharma employs about 6 people. The company is managed by 6 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Nexien Biopharma's management performance can provide insight into the firm performance.
| Joseph Morgan Insider Consultant |
| Esq JD Insider Chief Officer |
Nexien |
Nexien Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (5.9895) % which means that it has lost $5.9895 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (40.7045) %, meaning that it created substantial loss on money invested by shareholders. Nexien Biopharma's management efficiency ratios could be used to measure how well Nexien Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Nexien Biopharma Workforce Comparison
Nexien Biopharma is considered to be number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is now estimated at about 570. Nexien Biopharma claims roughly 6.0 in number of employees contributing just under 2% to equities under Drug Manufacturers—Specialty & Generic industry.
Nexien Biopharma Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Nexien Biopharma Price Series Summation is a cross summation of Nexien Biopharma price series and its benchmark/peer.
Nexien Biopharma Notable Stakeholders
A Nexien Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nexien Biopharma often face trade-offs trying to please all of them. Nexien Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nexien Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Joseph Morgan | Consultant | Profile | |
| Esq JD | Chief Officer | Profile | |
| Richard Greenberg | CEO, Founder | Profile | |
| Evan CPA | Chief Officer | Profile | |
| Paul Wilkenson | Consultant | Profile | |
| Linda Klumpers | Consultant | Profile |
About Nexien Biopharma Management Performance
The success or failure of an entity such as Nexien Biopharma often depends on how effective the management is. Nexien Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nexien management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nexien management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Nexien BioPharma, Inc. operates as a pharmaceutical company. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Nexien Biopharma Workforce Analysis
Traditionally, organizations such as Nexien Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nexien Biopharma within its industry.Nexien Biopharma Manpower Efficiency
Return on Nexien Biopharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 104.4K | |
| Net Loss Per Executive | 104.4K |
Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.